A confirmed case of leprosy has been identified in Cluj, with three additional suspected cases under investigation. The Ministry of Health has announced firm measures and emphasized that the risk to the general population remains low.
Bucharest to Host the 12th Pharmacovigilance Workshop in October 2025
Bucharest will host the 12th Pharmacovigilance Workshop on 27–29 October 2025, featuring EMA updates, case studies, and hybrid participation options.
The National Agency for Medicines and Medical Devices of Romania (ANMDMR) announces the organization of the 12th Pharmacovigilance Workshop, which will take place in Bucharest from 27 to 29 October 2025. The event will cover key updates, including EMA news, Product Management Service (PMS), benefit-risk assessment, MedDRA, and the use of real-world data for regulatory safety decisions.
The workshop will be delivered in English by Dr. Călin A. Lungu, along with other international speakers: Dr. Mircea Ciucă (Organon, Switzerland), Dr. Marco Sardella (Adienne, Italy), and Prof. John Borg (Malta Medicines Agency, Malta). Depending on international registrations, the event may be organized in a hybrid format (on-site and online).
The full agenda and registration details are available on the ANMDMR website: Agenda and Registration Information.
Medic24 - Romania's healthcare system at a glance
Romania surpasses 1,500 thrombectomies in 2025 as AP-AVC funding rises and the national stroke-treatment network expands.
The Ministry of Health announces a national first: Romania’s first mobile MRI system has been put into operation at the Nicolae Oblu Emergency Clinical Hospital in Iași, allowing high-performance imaging investigations to be carried out directly in the operating room and in intensive care.
CNAS data show major increases in vaccination in 2025, including +49% for HPV and +121% for meningococcal vaccines, signalling renewed trust in prevention.
Romania faces Europe’s highest cervical cancer burden. Updated 2025 data on incidence, screening, HPV vaccination and key policy challenges.
Antibiotice Iași invests €75 million in a new research and production center for critical medicines, supported by Romania’s Health and Investment Ministries through the STEP program.
